about
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Recurrent ovarian cancer.
@en
type
label
Recurrent ovarian cancer.
@en
prefLabel
Recurrent ovarian cancer.
@en
P2860
P356
P1433
P1476
Recurrent ovarian cancer.
@en
P2093
E Pujade-Lauraine
P2860
P304
P356
10.1093/ANNONC/MDW079
P478
27 Suppl 1
P577
2016-04-01T00:00:00Z